Biogen’s Henshaw Insists Data Is Key In Bolstering Biosimilars

Data published by Biogen is a key factor in driving uptake and acceptance of its biosimilars, the firm’s head of biosimilars, Ian Henshaw, told Generics Bulletin in an exclusive interview.

Interface
Biogen’s Ian Henshaw Says Data Can Be As Important As Price In Driving Uptake • Source: Shutterstock

Around €1.8bn ($2.02bn) in European healthcare cost savings are expected in 2019 from uptake of Biogen’s anti-TNF biosimilars portfolio of Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), according to the latest figures revealed by the firm at the European Congress of Rheumatology, EULAR.

At the same time, the firm has released a series of nine abstracts detailing real-world data from the biosimilars portfolio developed through its Samsung

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Products